Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
BioViotica
Fumitremorgin C
100
CHF
CHF 100.00
In stock
BVT-0189-C250250 µgCHF 100.00
BVT-0189-M0011 mgCHF 185.00
| Product Details | |
|---|---|
| Synonyms | FTC; Tryptoquivaline |
| Product Type | Chemical |
| Properties | |
| Formula |
C22H25N3O3 |
| MW | 379.5 |
| CAS | 118974-02-0 |
| Source/Host Chemicals | Isolated from Aspergillus fumigatus. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to light brown powder. |
| Solubility | Soluble in DMSO, methanol, acetone, DMF or chloroform. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by BioViotica. |
| Other Product Data |
A concentration of 1mg/ml is recommended for stock solutions. |
| InChi Key | DBEYVIGIPJSTOR-FHWLQOOXSA-N |
| Smiles | [H][C@@]12CCCN1C(=O)[C@]1([H])CC3=C(NC4=C3C=CC(OC)=C4)[C@H](C=C(C)C)N1C2=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light when in solution. |
| Use/Stability |
Stable for at least 1 year after receipt when stored at +4°C. After reconstitution protect from light at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Mycotoxin.
- Cytotoxic.
- Tremorgenic.
- Potent and specific inhibitor of the breast cancer resistance protein (BCRP; ABCG2).
- Reverses multidrug resistance mediated by BCRP and increases cytotoxicity of several anticancer agents in vitro.
Product References
- Mycotoxins produced by Aspergillus fumigatus species isolated from molded silage: R.J. Cole, et al.; J. Agric. Food Chem. 25, 826 (1977)
- Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. I. Taxonomy, fermentation, isolation and biological properties: C.B. Cui, et al.; J. Antibiot. 49, 527 (1996)
- Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin: S.K. Rabindran, et al.; Cancer Res. 58, 5850 (1998)
- Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.: S.K. Rabindran, et al.; Cancer Res. 60, 47 (2000)
- Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.:Ozvegy, et al.; J. Biol. Chem. 277, 47980 (2002)
- The role of breast cancer resistance protein in acute lymphoblastic leukemia: S.L. Plasschaert, et al.; Clin. Cancer Res. 9, 5171 (2003)
- Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors: T.S. Garimella, et al.; Cancer Chemother. Pharmacol. 55, 101 (2005)
- Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes: S. Hauswald, et al.; Clin. Cancer Res. 15, 3705 (2009)
- Specific inhibitors of the breast cancer resistance protein (BCRP): A. Pick, et al.; ChemMedChem 5, 1498 (2010)
- Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C: L. Gonzales-Lobato, et al.; Eur. J. Pharmacol. 644, 41 (2010)
- Cytotoxic compounds from the marine-derived fungus Aspergillus sp. recovered from the sediments of the Brazilian coast: N. N. Saraiva, et al.; Nat. Prod. Res. 29, 1545 (2014)
- Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells: H.L. Huang, et al.; Oncol. Lett. 9, 1287 (2015)
- The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets: K. Ito, et al.; Cell Rep. 39, 110721 (2022)
Related Products
